Kamada (NASDAQ: KMDA) will release first quarter 2026 financial results for the period ended March 31, 2026, before U.S. markets open on May 13, 2026. Management will host an investor conference call on May 13 at 8:30am ET and a live webcast will be available.
Dial-in numbers and conference ID 13760232 are provided for U.S., Israel, and international participants; the call will be webcast at the company's public webcast link.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – KMDA
+0.85%
+0.85%Session close to close
In the May 6 session, KMDA gained 0.85%, reflecting a mild positive market reaction.
This announcement schedules Kamada’s first quarter 2026 results for release on May 13, 2026, with an...
Analysis
This announcement schedules Kamada’s first quarter 2026 results for release on May 13, 2026, with an investor call at 8:30am ET. It follows record 2025 financials, initiation of a recurring cash dividend, and FDA approval of a new plasma collection center. Investors may focus on how Q1 performance tracks against the company’s 2026 guidance and ongoing strategic initiatives highlighted in recent filings and press releases.
Key Figures
Results date:May 13, 2026Quarter end:March 31, 2026Conference time:8:30am ET+5 more
8 metrics
Results dateMay 13, 2026Q1 2026 financial results release before U.S. market open
Quarter endMarch 31, 2026First quarter 2026 reporting period
Conference time8:30am ETInvestment community call to discuss Q1 2026 results
U.S. dial-in1-877-407-0792Domestic access number for the Q1 2026 results call
Israel dial-in1-809-406-247Israeli access number for the Q1 2026 results call
International dial-in1-201-689-8263International access number for the Q1 2026 results call
Conference ID13760232Participant code for joining the Q1 2026 call
Webcast event ID1760803Identifier in the webcast URL for the live call
Announced FY and Q4 2025 results date with 8:30am ET investor call.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
The last earnings date announcement on Mar 4, 2026 was followed by a 2.91% positive 24-hour move.
Recent Company History
In recent months, Kamada reported record 2025 financial results with higher revenue, EBITDA, and net income, and introduced an annual cash dividend policy. It subsequently declared and clarified procedures for a $0.25 per‑share dividend of about $14.4M. The company also received FDA approval for its San Antonio plasma collection center. Against this backdrop, the current Q1 2026 earnings date announcement continues a pattern of regular financial disclosures and investor communications initiated earlier in 2026.
REHOVOT, Israel and HOBOKEN, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field, today announced that it will release financial results for the first quarter ended March 31, 2026, prior to the open of the U.S. financial markets on Wednesday, May 13, 2026.
Kamada management will host an investment community conference call on Wednesday, May 13, at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may participate in the call by dialing 1-877-407-0792 (from within the U.S.), 1-809-406-247 (from Israel), or 1-201-689-8263 (International) using conference I.D. 13760232. The call will be webcast live on the internet at: https://viavid.webcasts.com/starthere.jsp?ei=1760803&tp_key=7219e3b56c.
About Kamada Kamada Ltd. (the “Company”) is a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field. FIMI Opportunity Funds, the leading private equity firm in Israel, is the Company’s controlling shareholder, beneficially owning approximately 38% of the outstanding ordinary shares. The Company’s strategy is focused on driving profitable growth through four primary growth pillars: First, organic growth of its commercial portfolio, including continued investment in the commercialization and life cycle management of its proprietary products, consisting of six FDA-approved specialty plasma-derived products: KEDRAB®, GLASSIA®, CYTOGAM®, VARIZIG®, WINRHO SDF® and HEPAGAM B®, as well as KAMRAB®, and two equine-based anti-snake venom products. Second, distribution of third parties' pharmaceutical products in Israel & the MENA region through in-licensing partnerships, including the launch of several biosimilar products in Israel. Third, the Company is ramping up its plasma collection operations to support revenue growth through the sale of normal source plasma to other plasma-derived manufacturers, and to support its increasing demand for hyper-immune plasma. The Company currently owns three FDA-approved operating plasma collection centers in the United States, in Beaumont, Houston, and San Antonio, Texas. Fourth, the Company aims to secure new mergers and acquisitions, business development, in-licensing and/or collaboration opportunities, which are anticipated to enhance the Company’s marketed products portfolio and leverage its financial strength and existing commercial infrastructure to drive long-term profitable growth. The Company is leveraging its manufacturing, research and development expertise to advance the development and commercialization of additional product candidates, targeting areas of significant unmet medical need.
When will Kamada (KMDA) report Q1 2026 results and what is the schedule?
Kamada will report Q1 2026 results before U.S. market open on May 13, 2026. According to the company, management will hold an investor conference call on May 13 at 8:30am Eastern Time to discuss the results and take questions.
How can investors join the Kamada (KMDA) earnings conference call on May 13, 2026?
Investors can join by dialing designated numbers for the U.S., Israel, or international lines and using conference ID 13760232. According to the company, the call will also be available via a live webcast at the provided webcast URL.
What is the Kamada (KMDA) webcast link for the May 13, 2026 Q1 call?
The live webcast will be accessible at the company's public webcast URL provided for the event. According to the company, the webcast link opens the investor webcast player for the May 13, 2026 conference call.
What time is the Kamada (KMDA) investor call for Q1 2026 results in local U.S. time?
The investor call is scheduled for 8:30am Eastern Time on May 13, 2026. According to the company, that is the start time for management remarks and the live Q&A portion of the conference call.
Will Kamada (KMDA) discuss Q1 2026 financials live and answer shareholder questions?
Yes, management will discuss the Q1 2026 financial results and answer questions during the live investor conference call. According to the company, the session includes prepared remarks followed by a live question-and-answer period for participants.
